Cg Oncology, Inc.

Voting, dividend and liquidation rights of the holders of the common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock, of which there are none as of June 30, 2026 and December 31, 2025.

SEC original ↗Cg Oncology, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Dividends The holders of common stock shall be entitled to receive dividends out of funds legally available therefore at such times and in such amounts as the board of directors may determine in its sole discretion.

SEC original ↗Cg Oncology, Inc. — 10-Q Quarterly report10-QAug 6, 2026

In 2022, the Company established the 2022 Plan, under which the Company may grant options, restricted stock units, restricted stock, stock appreciation rights, dividend equivalents and other stock and cash-based awards to its employees and certain non-employees.

SEC original ↗Cg Oncology, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Debt In connection with the Conversion Event, the Company assumed an unsecured promissory note held by Biovire (the Biovire Note) with an outstanding principal balance of $ 3.0 million.

SEC original ↗Cg Oncology, Inc. — 10-Q Quarterly report10-QAug 6, 2026

(NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today reported financial results for the second quarter ended June 30, 2025, and provided business updates.

SEC original ↗Cg Oncology, Inc. — Earnings release (8-K exhibit)EX-99Aug 8, 2025

“We remain laser focused on bringing forward cretostimogene, our potentially breakthrough backbone treatment to patients.

SEC original ↗Cg Oncology, Inc. — Earnings release (8-K exhibit)EX-99Aug 8, 2025

About CG Oncology CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer.

SEC original ↗Cg Oncology, Inc. — Earnings release (8-K exhibit)EX-99Aug 8, 2025

(the Company) is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer.

SEC original ↗Cg Oncology, Inc. — 10-Q Quarterly report10-QAug 6, 2026

The recent positive outcome of the ANI litigation allows us to continue to focus our resources and energy on delivering this innovative therapy.

SEC original ↗Cg Oncology, Inc. — Earnings release (8-K exhibit)EX-99Aug 8, 2025

• Announced Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals: On July 29th, the Company announced that a jury in the Superior Court of the State of Delaware unanimously found in favor of CG Oncology on all claims in a March 2024 lawsuit brought by ANI Pharmaceuticals, Inc.

SEC original ↗Cg Oncology, Inc. — Earnings release (8-K exhibit)EX-99Aug 8, 2025

Legal Proceedings 32 Item 1A.

SEC original ↗Cg Oncology, Inc. — 10-Q Quarterly report10-QAug 6, 2026

These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

SEC original ↗Cg Oncology, Inc. — 10-Q Quarterly report10-QAug 6, 2026

These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of risks, uncertainties, and assumptions, including, without limitation, the risk factors described in Part I, Item 1A, Risk Factors of the 2025 Annual Report.

SEC original ↗Cg Oncology, Inc. — 10-Q Quarterly report10-QAug 6, 2026